Publications
Neuroendocrine Cancer
Survival benefit of extensive hepatic cytoreduction for symptomatic metastases from neuroendocrine tumors. Amersi F, Garza A, Bilchik AJ. Annals Surg Oncol (accepted).
Wolin, E.M. Neuroendocrine tumors of the Gastroentropancreatic Axis-commentary. (In press,2008). Principles and Practice of Surgical Oncology. Silberman, H. and Silberman, AW (Eds.) Lippincott, Williams, and Wilkins, Philadelphia(2008)
D. Cheng, N. Han, S. Mehdizadeh, E. Wolin, S. Colquhoun, N. Nissen, S. Lo. What Are the Most Useful Tools to Search for Primary Gastrointestinal Neuroendocrine Tumors (PGI-NET)? Gastrointestinal Endoscopy, Volume 65, Issue 5, Pages AB344-(2008)
M. W. Sung, L. Kvols, E. Wolin, G. Jacob, C. Talluto, J. C. Torres, A. Parta, E. Rodriguez, R. Shepard. Phase II proof-of-concept study of Atiprimod in patients with advanced low to intermediate grade neuroendocrine carcinoma (ASCO, 2008)
E Wolin, L Kvols, S Ezzat, W Kocha, E Van Cutsem, U Schoenherr, R Fandi. Pasireotide LAR In Patients With Metastatic Carcinoid Tumors: Interim Safety Results From A Randomized, Multicenter Phase I Study. 10th World Congress on GI Cancer in Barcelona, Spain on 25-28 June 08
Martina Zalom, Jessica Lee, Alan Waxman, Alessandro D'Agnolo, Nicholas Nissen, Dara Canata, Run Yu, Michael Lill, Edward Wolin. Metabolic and Receptor Imaging in Predicting Clinical Outcomes for Patients with Neuroendocrine Tumors: Comparison of FDG-PET with Indium-111 Pentetreotide.. (Submitted for publication in 2008)
